Guidelines for Maternal Thromboembolism Prevention

Abstract

Maternal thromboembolism, encompassing both venous thromboembolism (VTE) and arterial events, remains a significant contributor to maternal morbidity and mortality globally. This review synthesizes current epidemiological data, elucidates underlying pathophysiology, outlines risk stratification, and provides a comprehensive overview of clinical features, diagnostic challenges, and evidence-based management. Emphasis is placed on recent advances and guideline-driven recommendations for prevention, tailored to the unique physiological changes of pregnancy and the postpartum period. The article offers clinicians pragmatic insights for optimizing maternal outcomes.

Introduction

Pregnancy and the puerperium present a hypercoagulable state, predisposing women to thromboembolic events. Thromboembolism is one of the leading causes of maternal death in developed countries, necessitating robust preventive strategies. Clinical vigilance, risk assessment, and adherence to evolving guidelines are critical to reducing the burden of maternal thromboembolism. This article reviews the pathophysiological basis, risk factors, and evidence-based preventive interventions, with a focus on translating guideline recommendations into clinical practice.

Epidemiology / Disease Burden

The incidence of VTE in pregnancy is estimated at 1 to 2 per 1000 pregnancies, with the risk highest during the postpartum period. Arterial thromboembolism, though less common, also poses significant risks. Maternal VTE accounts for 10–15% of maternal deaths in developed nations. Ethnic disparities exist, with higher rates observed in women of African and South Asian descent. Recent surveillance data highlight that improved obstetric care and thromboprophylaxis protocols have reduced, but not eliminated, the incidence of maternal thromboembolism.

Pathophysiology

Physiological changes in pregnancy increase thromboembolic risk through multiple mechanisms. Elevated estrogen levels enhance hepatic synthesis of clotting factors (VII, VIII, X, and fibrinogen), while natural anticoagulants such as protein S decrease. Venous stasis arises from gravid uterine compression of pelvic veins, and vascular endothelial injury may occur during labor and delivery. Together, these satisfy Virchow\"s triad: hypercoagulability, stasis, and endothelial dysfunction. These changes persist into the postpartum period, maintaining elevated risk for up to six weeks after delivery.

Risk Factors

Risk factors for maternal thromboembolism include advanced maternal age, obesity (BMI ≥ 30 kg/m²), personal or family history of VTE, inherited or acquired thrombophilias (e.g., Factor V Leiden, antiphospholipid syndrome), multiparity, prolonged immobilization, cesarean section, preeclampsia, and smoking. Assisted reproductive technologies and multiple gestations further augment risk. Stratification tools, such as those developed by the Royal College of Obstetricians and Gynaecologists (RCOG), facilitate individualized risk assessment and guide prophylactic strategies.

Clinical Features

Maternal VTE most commonly presents as deep vein thrombosis (DVT) or pulmonary embolism (PE). DVT typically involves the left lower limb and manifests as unilateral swelling, pain, warmth, and erythema. PE may present with sudden-onset dyspnea, chest pain, tachypnea, tachycardia, syncope, or, in severe cases, circulatory collapse. Clinical diagnosis is challenging due to physiological changes in pregnancy that may mimic or mask symptoms, underscoring the need for high clinical suspicion.

Diagnosis

Diagnostic evaluation is complicated by overlapping symptoms and the need to minimize fetal radiation exposure. Compression ultrasonography is the first-line modality for suspected DVT. For suspected PE, ventilation-perfusion (V/Q) scanning or computed tomography pulmonary angiography (CTPA) may be employed, with preference determined by local protocols and patient-specific contraindications. D-dimer levels, often elevated in pregnancy, have limited diagnostic utility. A multidisciplinary approach involving obstetricians, hematologists, and radiologists is recommended for complex cases.

Treatment & Management

Low molecular weight heparin (LMWH) is the anticoagulant of choice for both prophylaxis and treatment due to its safety profile, predictable pharmacokinetics, and lack of placental transfer. Unfractionated heparin may be preferred in certain high-risk or peripartum settings. Warfarin is contraindicated in pregnancy due to teratogenicity but may be considered postpartum. Duration of therapy is typically 6 weeks postpartum or a minimum of 3 months. Mechanical prophylaxis, such as graduated compression stockings, is considered for those with contraindications to pharmacologic agents. Multidisciplinary management is essential for optimizing maternal and fetal outcomes.

Recent Advances / Emerging Therapies

Recent years have seen refinements in risk assessment models and dosing regimens. Individualized thromboprophylaxis, incorporating both clinical and genetic risk factors, is an emerging paradigm. Direct oral anticoagulants (DOACs) are not currently recommended due to insufficient safety data in pregnancy, but ongoing trials may refine their role. Advances in diagnostic imaging have reduced fetal radiation exposure, and point-of-care ultrasonography is increasingly utilized. Biomarker research aims to enhance risk stratification and early diagnosis in the future.

Guideline Recommendations

Professional societies, including the American College of Obstetricians and Gynecologists (ACOG), RCOG, and the Society of Maternal-Fetal Medicine, recommend universal risk assessment at the first prenatal visit and reassessment during pregnancy and postpartum. Pharmacologic prophylaxis is recommended for women with previous VTE, high-risk thrombophilias, or multiple moderate risk factors. Prophylaxis should continue for at least 6 weeks postpartum in high-risk women. Cesarean delivery confers a two- to fourfold increased risk, warranting special consideration. Guidelines emphasize individualized care and patient education to optimize adherence and outcomes.

Conclusion

Maternal thromboembolism remains a leading cause of preventable morbidity and mortality. Understanding the unique pathophysiological, clinical, and diagnostic aspects of pregnancy-related thromboembolism is essential for effective prevention. Adherence to guideline-based risk assessment and prophylactic strategies, coupled with multidisciplinary collaboration, is paramount. Ongoing research and emerging technologies promise to further refine prevention and management, improving safety for both mothers and infants.